Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: MichBio News

As Michigan Life Sciences Industry Awaits Exits, Focus Shifts to Later-Stage Funds, Talent

Tuesday, November 1, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

The availability of scientific and executive management talent and the access to later-stage investment capital remain major issues for Michigan’s life sciences industry.

That capital gap is worst when it comes to securing large financing rounds from in-state sources for life sciences companies that were seeded years ago and have moved down the product development pathway, according to industry professionals MiBiz gathered this month for an executive roundtable discussion.

The discussion — held at the downtown Kalamazoo office of law firm Honigman Miller Schwartz and Cohn LLP, which sponsored the roundtable — included:

  • David Esposito, president and CEO of Kalamazoo-based Armune Bioscience Inc.
  • Dr. Tim Fischell, CEO and chief medical officer at Ablative Solutions Inc. in Kalamazoo
  • Dale Grogan, a managing partner at Charter Capital Partners in Grand Rapids and Michigan Accelerator Fund I
  • Jim Medsker, president of Keystone Solutions Group in Kalamazoo, a product development firm and contract manufacturer of medical devices
  • Stephen Rapundalo, CEO of the Ann Arbor-based trade association MichBio
  • Phil Torrence, a partner at Honigman in Kalamazoo whose practice specializes in life sciences.

Read full article.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal